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Abstract
We provide a brief review of research on chronic kidney disease and cognitive performance,
including dementia. We touch briefly on the literature relating end-stage-renal disease to cognitive
function, but focus on studies of modest and moderate forms of chronic kidney disease (CKD) that
precede dialysis and transplantation. We summarize previous reviews dealing with case control
studies of patients but more fully examine community-based studies with large samples and
necessary controls for demographic risk factors, cardiovascular variables, and other confounds
such as depression.
In addition we suggest potential biological and social-psychological mediators between CKD and
cognition. Studies follow in two categories of design: (1) cross-sectional studies; (2) longitudinal
studies. In each, CKD is related to a wide range of deficits in cognitive functioning including,
verbal and visual-memory and organization, and components of executive functioning and fluid
intellect. In general, prior to the need to treat with hemodialysis (HD) or kidney transplant (KT),
magnitude of effect with relation to CKD and function are small or modest in persons free from
acute stroke and dementia. However, HD and KT can result in major impairment. We discuss
needed controls, the greater demand on controls after HD and KT begin, and suggest that
mechanisms intervening relations between hypertension, or diabetes, and cognitive performance
may be similar to those intervening between hypertension and cognitive performance and the
hypertension and diabetes literature on cognition provides a good model for the study of early
stage kidney disease and cognitive ability. We posit that the mechanisms linking CKD and
cognition may be similar to those linking hypertension or diabetes to cognition.
We identify the need for more studies with multiple cognitive test batteries, measures of every-day
cognitive abilities relevant to patient understanding of the disease and treatments, and more
studies with prevalent and incident dementia outcomes.
Descriptors
kidney disease; chronic kidney disease; cognitive function; dementia; cardiovascular risk factors
A new case of dementia occurs every four seconds world-wide, which is equivalent to 7.7
million cases each year, and mild cognitive impairment is even more prevalent [1]. Chronic
kidney disease (CKD) is a risk factor (RF) for dementia and cognitive impairment [2, 3–5].
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Cognitive impairment detracts from quality of life and is a risk factor for dialysis-related
mortality [6]. In this brief review we summarize the literature on CKD in relation to
cognitive function, discuss intervening mechanisms, and comment on some methodological
issues, but refer the reader to other reviews of the many studies comparing treatments such
as hemodialysis (HD), peritoneal dialysis (PD) and transplantation. We emphasize a pre-
treatment stage of CKD, but include studies examining modest to severe CKD.
Renal Functioning Predictors of Cognitive Function
Renal disease is well-defined in previous reviews [2,3–5,7]. Table 1 summarizes commonly
used predictor variables in cognitive studies and the measurement metrics used to define
them. Common predictors are estimated glomerular filtration rate (eGFR), serum creatinine
(sCR) and far less commonly stages of renal disease [2] involving measures such a
proteinuria, biopsy or structural imaging.
Cognitive Outcomes in Renal Studies
A previous review provides a list of tests commonly used in the renal literature [3] and other
reviews illustrate how multiple tests should be used where the goal is to infer the locus of
brain impairment from one or more specific cognitive deficits [8,9]. Studies designed to
examine which abilities do and do not relate to a disease must examine a wide range of
different abilities [8,9]. Definitions of terms used in the psychometric literature are given in
Table 2. Outcome variables can be dichotomous (i.e., dementia, impairment, deficit), ordinal
categories of performance level, or continuously distributed test scores representing
performance level. We use the term cognitive impairment only if this cognitive status has
been established by clinical criteria, i.e., neuropsychological (NP) evaluation and/or
normative data. The term deficit is used as a comparative term indicating a lower average
level of performance relative to a reference group or groups. The term decline is only used
for longitudinal change in performance.
Overview: End Stage Renal Disease (ESRD) and Treatment
We refer to the reader to previous reviews [2,3–5] for a summary of this literature. However,
it is important to note that an estimated 70% of hemodialysis (HD) patients over age 55
exhibit moderate to severe cognitive impairment [5] with a similar prevalence for peritoneal
dialysis (PD) patients [10]. Griva et al. [6] reported that two-thirds of a community-dwelling
sample of 145 PD, home-dialysis and in-center HD patients in London, UK suffered from
what the authors defined as mild or moderate cognitive impairment: 1.00–1.99 and 2–2.99
SD below the mean, respectively. We agree with Murray and Knopman [5] that performance
2.00 SD below the mean (3% of the population fall here) is not moderate, but is reflective of
clinically significant cognitive dysfunction. Comprehensive reviews of this literature
indicate that HD, PD and transplantation are associated with wide ranging deficits in
attention, memory, speed of performance, and components of executive functioning (EF)
[4,5], although it is clear that adverse cognitive outcomes are attenuated when cognitive
testing is timed properly in relation to dialysis treatment [2].
There have been few studies of practical every-day cognitive tasks and kidney disease.
Numeracy skills are critical to advance planning necessary to comply with treatment
regimens and disease understanding [11]. Numeracy refers to the degree that one can apply
statistical, graphical and numerical skills in such a way as to effectively understand and
comply with health information [11]. Abdel-Kader et al. [11] found that the majority of 187
ESRD patients (mean age=52 years) exhibited low numeric efficiency on a 3-item scale.
Grubbs et al. [12] reported a 32.3% prevalence of inadequate health care literacy in a sample
of 62 dialysis patients. Gelb and colleagues [13], in a study of 108 kidney transplant
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recipients, reported that lower levels of performance on every-day problem solving tests and
number of depressive symptoms were associated with poor medication adherence, but found
no association with multiple NP measures and adherence. These studies were not
prospective and thus the direction of these associations needs to be defined in future studies.
In summary, the history of cognitive deficit and impairment begins prior to the transition to
ESRD [5]. Once ESRD status has been reached and dialysis has begun, the demands on
design and control become increasingly complex and thus the early or pre-treatment stages
of CKD provide an important window of investigation.
Cross-Sectional Community-Based Studies
We have chosen to focus on the community-based studies given the very much larger
samples, statistical adjustment for CVD and absence of sample bias introduced by multiple
exclusions in order control for differences in health factors among uremic samples, healthy
controls and patient groups.
Table 5 summarizes methodological detail and results for the community-based studies
which began to appear in 2005. Earlier investigations emphasized case-control type studies
that compared uremic patients to other diagnostic groups, e.g., medical and psychiatric
patients or healthy controls [2]. A major review of this case-control literature[2] indicates
that uremic patients, compared to general medical and psychiatric groups, performed better
on measures of motor speed, auditory alertness and crystallized intelligence and performed
more poorly on measures of cognitive flexibility and other components of EF, verbal
memory and learning, visual attention and fluid intelligence. In 3 of the case-control studies
reviewed by Koushik et al. [2], levels of performance were not below average when
compared to normative data. In some case-control studies exclusion for health factors were
extensive, e.g. [14], but often the major controls were for age, education, and sex [2].
In each of the community-based studies (Table 3) there were controls (exclusion or
adjustment) for demographic variables, CVD risk factors, or health factors, and other
confounders. Estimated eGFR levels <60, versus ≥60 were associated with deficits in global
cognitive performance. Studies prior to 2009 reported that higher levels of eGFR were
associated with deficits in language, memory, components of EF [15,16], learning and
concentration [15], visual attention [15], psychomotor efficiency and processing speed [17],
and global impairment on a telephone interview scale [18]. While sample sizes were
impressive, the cognitive batteries were limited, sometimes involving only one or a few
tests.
To address this issue, Elias et al. [19] using the Maine Syracuse Longitudinal Study
(MSLS), employed 923 dementia-free community-dwelling individuals and 19 widely-used
clinical cognitive tests in a factor analysis leading to the identification of the following
outcome variables: (1) a global composite test score; (2) four composite scores or factors:
visual-spatial organization and memory, scanning and tracking (a component of executive
function), verbal memory, and working memory and (3) a single measure of abstract
reasoning (WAIS Similarities) which loaded with approximately equal strength on each
composite. Persons undergoing dialysis (n=4) and/or diagnosed with dementia (n=9) were
excluded. For an analysis adjusting for demographic factors, CVD, and acute stroke, higher
sCR values were associated with lower levels of performance for global performance, verbal
episodic memory and scanning and tracking. For example increments in creatinine of 2 mg/
dL were associated with a decrement of 0.12 SD in performance level. Moreover, the odds
ratios (ORs) associated with poor global performance (defined as the lowest quartile of the
distribution of test scores) were OR=2.27 with control for age, sex, education, and race and
OR=1.97 with additional adjustment for CVD and stroke.
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In summary, community-based, large sample, cross-sectional studies support the
generalization that mild and modest kidney disease is related to modest deficits in multiple
cognitive abilities. As in the hypertension literature, crystallized intellect appears to be
spared in studies of dementia-free samples [19]. The limitation of each of these studies is
that they were cross-sectional and only two studies specifically reported excluding of
dialysis patients [19,20] or those with eGFR<30 [15].
Longitudinal Studies
Longitudinal studies of community-based samples after 2004 are summarized in Table 4.
These studies measure change in cognitive functioning over time. Studies are arranged by
outcomes: (1) level of cognitive performance, (2) binary levels of performance where
decline in performance is based on poor performance at followup defined arbitrarily or in
terms of normative data; (3) binary or gradations of certainty with regard to probable
dementia. The first two categories are important to the third because lower cognitive
performance in persons free from acute stroke and dementia is a risk factor for dementia
[21]. The studies cited have relatively good controls as defined by adjustment for age, sex,
education, and race, where relevant, and extended models which consider health variables,
cardiovascular risk factors or events (e.g. stroke). Table 5 provides a check-list summary of
results for papers summarized in Table 4. Each of the studies [20,22–28, Note 1] reported
that baseline levels for at least one predictor was related to cognitive decline, impairment or
dementia, except for Slinin et al. [29] who obtained negative results with adjustment for age.
Davey et al. [Note 1] with the smallest longitudinal sample (N= 590), but with a
comprehensive cognitive test battery, did not find longitudinal change in cognitive
performance from baseline to followup. However, a decline in renal function over time
(indicated by eGFR or sCR) was related to decline in global cognitive performance, verbal
memory and abstract reasoning. Negative findings relative to decline in cognitive
performance relative to baseline levels of renal function are not readily explained by study
length or number of cognitive measures. Relative to other studies, Davey et al. [Note 1]
featured the largest number of cognitive outcomes and a fairly long followup of 4 to 5 years.
But the sample was relatively well-educated and change in renal function may be more
sensitive in terms of cognitive change than baseline levels. Following 2406 participants over
4 years, Helmer et al. [23] also found that change in renal function over 4 years but not
baseline renal function was related to longitudinal decline (incident dementia).
None of the longitudinal studies used an every-day measure of cognitive performance or
employed numeracy as a predictor or covariate and only 5 of the 16 studies summarized in
Tables 4 and 5 adjusted for clinical depression or depressed mood.
Obviously there is a need for more studies with comprehensive test batteries, longer
longitudinal followup periods and stratification by education level and/or numeracy skill,
and with explicit exclusion of renal dialysis patients. Yet considering these studies
collectively, it is clear that depending on severity of renal disease and the general health of
the study population, various indices of CKD prevalence are related to decline in cognitive
performance over time and dementia in samples over 65 years of age. What is not known
from current studies is the prevalence, incidence or rate of cognitive decline prior to
dementia.
Note 1Davey, A, Elias, MF, Robbins, A, Seliger, SL, Dore GA. Decrease in renal functioning is associated with longitudinal decline
in global cognitive functioning, abstract reasoning, and verbal memory. Unpublished Manuscript, Submitted to Nephrol Dial
Transplant, revised and under re-review.
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It is encouraging to find that in the study of relatively well-educated non-demented
community-based subjects, dialysis excluded, decline in performance levels over 4 to 5
years was modest and not such that they would interfere with understanding and adherence
necessary to the treatment of renal disease [Note 1].
Mechanisms Relating Kidney Disease to Cognition
Table 6 lists variables that may mediate between renal disease and cognitive function. One
may hypothesize, among other models, direct paths in which CKD affects brain function and
morphology and hence cognition. An alternative, and not mutually exclusive, possibility is
that risk factors shared by brain and kidney lead to cognitive deficit, decline and impairment
[30]. This parallel risk factor model is appealing because “both kidney and brain are low
resistance end-organs and are exposed and re-exposed to high-volume blood flow though the
cardiac cycle” [30 p.5]. Thus the brain and kidney very likely share common risk factors for
cognitive deficit and impairment. It is clear that the issue of mediating variables becomes
complex once treatment is initiated for ESRD. Thus we refer the reader to a comprehensive
model by Murray & Knopman [5] and in Table 6 summarize the many candidate
mechanisms. In pre-treatment forms of renal disease it makes some sense that the search for
mechanisms should begin with the strongest risk factors for kidney disease, i.e.,
hypertension and diabetes. However, few if any mediation studies have been undertaken.
Methodological Issues
Controls
Controls for age, education, sex, and where relevant, race and ethnic composition are
imperative, and controls for prevalent CVD risk factors, including depressed mood or
clinical depression, and CVD events (e.g. acute stroke) are very important. But inspection of
Table 6 indicates that many other potential confounders exist even where the focus is pre-
ESRD kidney disease. Polypharmacy is highly prevalent in the elderly. Moreover, many
social psychological factors that are correlated with renal disease are especially important
when patient groups or non-patients are employed as control groups.
Cognitive Measurement
The finding that renal disease is related to multiple cognitive abilities, with few exceptions
(e.g. over-learned crystallized intelligence), may be related to the fact that renal disease has
a diffuse effect on brain function. However, it is important to recognize that the clinical
cognitive tests traditionally employed in research on disease are impure, i.e., they measure a
mixture of intended and untended cognitive constructs. Clinical cognitive tests are highly
correlated with each other and with tests of general intellectual functioning [9]. There are
two solutions: (1) factor analyses that identify theoretically-relevant cognitive domains, e.g.
[19], and (2) utilization of more precise information processing tasks [9]. The latter method
increases measurement purity but also increases performance difficulty for poorly educated
study participants, makes significant demands on study time, and is less clinically
interpretable.
Clinical Implications
In general, pre-dialysis and pre-transplant levels of cognitive deficit are relatively modest in
well cared for and relatively highly educated, dementia- and stroke-free community samples,
e.g., [19,22]. This is good news and suggests that intervention might possibly be effective in
preventing or delaying more serious ESRD and ESRD-treatment related cognitive deficit
and impairment [4,5]. This conclusion is tentative pending more studies and clinical trials.
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Summary
Prior to ESRD and treatment, kidney disease can result in global and multiple, specific-
cognitive deficits, often mild, but sometimes associated with dementia. Treatment methods
are improving but the physiological consequences of treatment can lead to more severe
deficit. Biological factors intrinsic to renal disease, psychosocial factors, and polypharmacy
are candidate intervening mechanisms, but formal studies identifying mediators between
mild and modest levels of kidney disease and cognition have not been done.
We are starting down the path of a complex and challenging area of research and have a
long way to go. We are in a descriptive phase of research, albeit we need more studies with
comprehensive batteries of cognitive tests and tests of every-day cognitive function. To our
knowledge, there have been no randomized-to-treatment clinical trials addressing
improvement in cognitive performance with treatment for CVD risk factors. The clinical
trial literature on hypertension provides a good model for this important next step.
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Table 1
Definitions of terms used in this review.
Tern Definition
Construct The theoretical mental process that tests attempt to measure or index.
Decline Change in performance level from better to worse over time.
Deficit A relative decrement in performance that does not rise to the level of impairment, e.g. mean level of
performance in a group is lower than mean level of performance in another group, but individual differences in
performance may overlap among groups.
Dementia A progressive cognitive impairment characterized by decline in memory ability and impairment in one or more
other cognitive domains, e.g., language, orientation, reasoning, attention and executive functioning (EF).
Represents a decline from a previous level of functioning and interferes with activities of daily living and
independence. Alzheimer’s Disease (AD) is the most common form and a major risk factor is amnestic MCI.
Domain A composite set of skills measured (indexed) by more than one test of specific ability as may be identified by
factor analysis.
Every-Day ability A test that measures real-life activities such as map reading, check balancing, following directions, organizing
medications.
Executive Function The ability to anticipate, plan and organize and to reject old inappropriate responses for new appropriate
responses when confronted with a new problem. Difficult to separate from fluid intelligence and often and
erroneously used as isomorphic with frontal lobe function, although frontal lobe damage is associated with
poorer EF.
Fluid Intelligence Ability with regard to dealing with new and novel tasks as opposed to crystallized (verbal intelligence) ability,
often with demands on speed of performance. Many reviews of the literature have emphasized the extreme
difficulty of separating fluid intelligence from executive functioning [EF] given their significant overlap in
abilities measured [ref number here]
Global Ability Overall ability which is the synergistic combination of specific abilities, e.g. overall score on an intelligence test.
Impairment Poor performance reaching a clinically important level of deficit as defined by neuropsychological assessment
and/or normative data.
Impurity Failure of a test to measure only abilities it was designed to measure.
Level of Performance An average or median level of performance based on the entire distribution of test scores or normative data.
Mental Status Ability measured by screening measures such as the Mini Mental Status Examination (MMSE), often described
as a test of global ability but lacking in sensitivity and specificity relative to intelligence test measures.
Mild Cognitive Impairment Mild Cognitive Impairment (MCI) is a level of performance that indicates decline from a previous level of
performance and impairment by clinical/normative criteria, but does not rise to the level of dementia.
Individuals with MCI typically remain in the community and do not necessarily exhibit general intellectual
decline. There are at least 30 different definitions formal clinical definitions in the literature.
Short Form A shorter form of a test designed to retain validity and reliability but normally looses both to some extent.
Specific Ability Ability in a relatively narrow range of specialized functioning as opposed to global cognitive ability or general
intelligence.
Vascular Dementia (VaD) Memory decline may be present but not necessarily predominant and other cognitive domains are affected early
in the disease process and in the MCI that precedes it. Progress of VaD is more varied over time than is the
progress of AD and a history of CVD risk factors and events are common. AD has a vascular component and
mixed dementias are common.
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Table 2
Common predictor variables in studies of renal disease and cognitive performance,
Predictor Metric or Type of Measurement Type of Variable
Uremic Patient1 vs Controls Diagnostic criteria Categorical
eGFR2 mL/min per 1.73m2 body surface Categorical4 or continuous.
Serum Creatinine (sCR) mg/dL or μmol/L Continuous5
Stage of Kidney Disease3 Standard Diagnostic Criteria Categorical
1Uremia defined as the accumulation of urinary waste products in the urine or the constellation of signs and symptoms indicating kidney disease or
failure.
2
eGFR (estimated glomuerular filtration rate) be estimated via different formulae: Modification of Diet in Renal Disease (MDRD) study equation
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation Mayo Clinic Quadratic equation
3See reference 5 for definitions and criteria.
4Studies often use eGFR ≥60 (mL/min/1.73m2) versus <60, or, for example, normal (≥90); mildly decreased (60 to 89); moderate CKD (30–59),
severe CKD (15 to 29) and kidney failure (<15), or clinical criteria, tertiles, quartiles, quintiles etc.
5Continuously distributed such as eGFR in units (ml/min/1,73m2) or sCR in units (1 mg/dL) expressed as 1/sCR due to skew. [see reference 26 as
example].
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ra
ng
ed
 b
y 
da
te
 o
f p
ub
lic
at
io
n.
A
ut
ho
rs
D
es
ig
n
O
ut
co
m
es
C
on
tr
ol
 o
r A
dju
stm
en
t
Su
m
m
ar
y 
of
 F
in
di
ng
s
K
ur
el
la
 e
t a
l. 
(20
05
)
[1
6]
1,
10
5 
co
m
m
un
ity
-d
w
el
lin
g 
po
st-
m
en
op
au
sa
l
w
o
m
en
 (<
80
 ye
ars
) w
ith
 es
tab
lis
he
d
co
ro
n
ar
y 
ar
te
ry
 d
ise
as
e 
(no
 hy
ste
rec
tom
y)
en
ro
lle
d 
in
 th
e 
Es
tro
ge
n/
Pr
og
es
tin
R
ep
la
ce
m
en
t S
tu
dy
. C
K
D
 e
sti
m
at
ed
 u
sin
g
eG
FR
 a
s m
ild
 (4
5–
59
), m
od
era
te 
(30
–4
4)
an
d 
se
ve
re
 (e
GF
R<
 30
); 
eG
FR
 ≥6
0 w
as
re
fe
re
nt
 g
ro
up
.
M
ul
tip
le
 te
sts
 in
cl
ud
in
g
3M
S,
 T
ra
il 
M
ak
in
g 
Pa
rt 
B,
B
os
to
n 
N
am
in
g,
 V
er
ba
l
Fl
ue
nc
y,
 W
or
d 
Li
st 
M
em
or
y
an
d 
Re
ca
ll.
A
dju
stm
en
t fo
r a
ge
, ra
ce,
 ed
uc
ati
on
,
lif
es
ty
le
 fa
ct
or
s, 
str
ok
e,
 d
ia
be
te
s, 
an
d
o
th
er
 v
ar
ia
bl
es
 re
la
te
d 
to
 k
id
ne
y 
di
se
as
e.
eG
FR
 w
as
 a
ss
oc
ia
te
d 
w
ith
 d
ef
ic
its
 in
 g
lo
ba
l
co
gn
iti
on
, e
xe
cu
tiv
e 
fu
nc
tio
n,
 la
ng
ua
ge
, a
nd
m
em
o
ry
 (1
5 t
o 2
5%
 in
cre
me
nt 
in 
ris
k f
or 
de
fic
it
pe
r 1
0 
m
L/
m
in
/1
.7
3m
2  
de
cr
em
en
t i
n 
eG
FR
.
H
ai
lp
er
n 
et
 a
l.
(20
07
)[1
5]
Le
ve
l e
xp
re
ss
ed
 a
s
qu
ar
til
es
, r
ef
er
en
t
gr
ou
p 
is 
qu
ar
til
e
w
ith
 th
e 
po
or
es
t
pe
rfo
rm
an
ce
.
Y
ou
ng
er
, h
ea
lth
y 
an
d 
et
hn
ic
al
ly
 d
iv
er
se
co
m
m
u
n
ity
-b
as
ed
 a
du
lts
 re
cr
ui
te
d 
fro
m
 th
e
N
H
A
N
ES
 II
I (
ag
e r
an
ge
 20
–5
9; 
N 
ran
ge
47
21
 to
 4
86
5 
de
pe
nd
in
g 
on
 th
e t
es
t u
se
d).
M
od
er
at
e 
CK
D
 w
as
 d
ef
in
ed
 a
s e
G
FR
 3
0 
to
59
 w
ith
 eG
FR
> 
60
 as
 th
e r
ef
er
en
ce
 g
ro
up
.
Si
m
pl
e 
vi
su
al
-m
ot
or
re
ac
tio
n 
tim
e,
 v
isu
al
at
te
nt
io
n 
an
d 
le
ar
ni
ng
 a
nd
co
n
ce
n
tr
at
io
n 
te
sts
.
O
rd
in
al
 re
gr
es
sio
n 
an
al
ys
is,
 a
dju
stm
en
t
fo
r d
em
og
ra
ph
ic
 v
ar
ia
bl
es
 a
nd
 se
lf-
re
po
rte
d 
he
al
th
 v
ar
ia
bl
es
. D
ia
be
te
s
ex
cl
ud
ed
 in
 se
ns
iti
vi
ty
 a
na
ly
se
s.
M
od
er
at
e 
CK
D
 w
as
 a
ss
oc
ia
te
d 
w
ith
 p
oo
re
r
le
ar
ni
ng
 a
nd
 c
on
ce
nt
ra
tio
n 
(O
R=
 2.
4) 
an
d v
isu
al
at
te
nt
io
n 
(O
R=
 2.
7) 
wh
en
 ad
jus
ted
 fo
r a
ge
,
ge
nd
er
, e
du
ca
tio
n,
 ra
ce
, a
nd
 se
lf-
 re
po
rte
d
ge
ne
ra
l h
ea
lth
 a
nd
 o
th
er
 v
ar
ia
bl
es
 re
la
te
d 
to
CK
D
.
Ja
ss
al
 e
t a
l. 
(20
08
)
[1
7]
Pe
rfo
rm
an
ce
 le
ve
l
(te
st 
sco
res
).
99
 u
re
m
ic
 p
at
ie
nt
s (
me
an
 ag
e 6
5, 
wi
th 
50
%>
65
 y
ea
rs
) w
ith
 st
ag
e 3
 to
 5 
kid
ne
y d
ise
ase
 on
o
pt
im
iz
ed
 m
ed
ic
al
 tr
ea
tm
en
t a
t a
 p
re
-d
ia
ly
sis
cl
in
ic
. R
en
al
 fu
nc
tio
n 
de
fin
ed
 a
s e
G
FR
ca
lc
ul
at
ed
 a
s a
 c
on
tin
uo
us
ly
 d
ist
rib
ut
ed
v
ar
ia
bl
e.
M
ul
tip
le
 c
og
ni
tiv
e 
te
sts
 w
ith
co
m
po
sit
e 
sc
or
es
 m
ea
su
rin
g
th
re
e 
do
m
ai
ns
: a
tte
nt
io
n 
an
d
w
o
rk
in
g 
m
em
or
y;
ps
yc
ho
m
ot
or
 e
ffi
ci
en
cy
 a
nd
pr
oc
es
sin
g 
sp
ee
d;
 le
ar
ni
ng
ef
fic
ie
nc
y
A
dju
stm
en
t fo
r a
ge
, e
du
cat
ion
 an
d s
ex
,
co
m
o
rb
id
 d
ise
as
es
, h
em
og
lo
bi
n,
 P
TH
,
an
d 
nu
m
be
r o
f n
eu
ro
de
pr
es
so
r d
ru
gs
.
an
ti-
de
pr
es
sio
n 
m
ed
ic
at
io
n,
 p
ar
at
hy
ro
id
di
se
as
es
. S
en
sit
iv
ity
 a
na
ly
sis
 w
ith
 E
SP
S.
Ex
cl
us
io
ns
: h
ea
d 
in
jur
y, 
lea
rni
ng
di
sa
bi
lit
ie
s, 
hi
sto
ry
 o
f a
cu
te
 st
ro
ke
 a
nd
TI
A
, a
nd
 d
ep
re
ss
ed
 m
oo
d.
R
en
al
 fu
nc
tio
n 
(eG
FR
) w
as 
rel
ate
d t
o p
oo
rer
pe
rfo
rm
an
ce
 o
n 
te
st 
of
 p
sy
ch
om
ot
or
 e
ffi
ci
en
cy
an
d 
pr
oc
es
sin
g 
sp
ee
d 
w
ith
 st
at
ist
ic
al
 a
dju
stm
en
t
fo
r c
ov
ar
ia
te
s, 
bu
t w
as
 n
ot
 a
ss
oc
ia
te
d 
w
ith
pe
rfo
rm
an
ce
 sc
or
es
 fo
r a
tte
nt
io
n 
an
d 
w
or
ki
ng
m
em
o
ry
 o
r l
ea
rn
in
g 
ab
ili
ty
.
K
ur
el
la
 T
am
ur
a,
 e
t
al
. (2
00
8)[
18
]
23
,4
05
 co
m
m
un
ity
 –
 d
w
el
lin
g 
pa
rti
ci
pa
nt
s
(>
44
 ye
ars
) f
rom
 th
e R
EG
AR
DS
 St
ud
y.
CK
D
 d
ef
in
ed
 a
s <
 6
0.
 eG
FR
 in
 1
0-
 M
L/
m
in
/
1.
73
m
2  
in
cr
em
en
ts.
A
 si
x 
ite
m
 te
le
ph
on
e
sc
re
en
in
g 
te
st 
w
ith
 c
og
ni
tiv
e
im
pa
irm
en
t (
sic
.
 
de
fic
it)
de
fin
ed
 a
s a
 sc
or
e 
of
 <
4.
Ex
cl
ud
ed
 e
G
FR
 <
10
. A
dju
ste
d f
or 
ag
e,
ed
uc
at
io
n,
 se
x,
 ra
ce
, r
ec
ru
itm
en
t l
oc
at
io
n,
CV
D
 a
nd
 C
V
D
 ri
sk
 fa
ct
or
s.
CK
D
<6
0 
w
as
 as
so
ci
at
ed
 w
ith
 h
ig
he
r r
isk
 o
f
co
gn
iti
ve
 d
ef
ic
it 
(O
R=
 1.
23
). E
ac
h 1
-m
L/
mi
n
1.
73
m
2  
w
as
 a
ss
o
ci
at
ed
 w
ith
 a
n 
in
cr
em
en
t i
n
co
gn
iti
ve
 im
pa
irm
en
t (
OR
=1
.11
).
El
ia
s e
t a
l.1
 
(20
09
)
[1
9]
Pe
rfo
rm
an
ce
de
cr
em
en
t d
ef
in
ed
as
 th
e 
lo
w
es
t
qu
ar
til
e 
an
d 
al
so
pe
rfo
rm
an
ce
 le
ve
l
92
3 
co
m
m
un
ity
 d
w
el
lin
g 
pa
rti
ci
pa
nt
s (
> 4
0
ye
ar
s o
f a
ge
); 
co
mp
ari
so
ns
 be
tw
ee
n e
GF
R>
60
 an
d 
≤ 
60
; i
nc
re
m
en
t i
n 
sC
R 
fro
m
 1
 to
 2
m
g/
dL
, a
nd
 1
/sC
R 
as
 a
 c
on
tin
uo
us
ly
di
str
ib
ut
ed
 v
ar
ia
bl
e.
B
as
ed
 o
n 
19
 te
sts
 su
bm
itt
ed
to
 fa
ct
or
 a
na
ly
sis
.
Co
m
po
sit
e 
sc
or
es
 w
er
e
fo
rm
ed
 fo
r v
er
ba
l e
pi
so
di
c
m
em
o
ry
 (V
EM
), v
isu
al-
sp
at
ia
l m
em
or
y 
an
d
o
rg
an
iz
at
io
n,
 (V
SO
M
)
sc
an
n
in
g 
an
d 
tra
ck
in
g 
(S
T)
,
w
o
rk
in
g 
m
em
or
y 
(W
M
), a
nd
a 
gl
ob
al
 c
om
po
sit
e 
of
 a
ll
sc
o
re
s.
A
dju
ste
d f
or 
ag
e, 
ed
uc
ati
on
, se
x, 
rac
e,
di
ab
et
es
, s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
 B
M
I,
sm
o
ki
ng
, H
D
L 
an
d 
str
ok
e 
an
d 
ot
he
r r
isk
fa
ct
or
s i
n 
se
ns
iti
vi
ty
 a
na
ly
se
s.
Ex
cl
us
io
ns
: d
ia
ly
sis
, d
em
en
tia
, <
40
 y
ea
rs
o
f a
ge
.
Co
m
pa
ris
on
s o
f p
er
so
ns
 w
ith
 e
G
FR
 ≥
 6
0 
w
ith
eG
FR
< 
60
 in
di
ca
te
d 
de
cr
em
en
t f
or
 th
e l
at
te
r
gr
ou
p 
fo
r t
he
 g
lo
ba
l c
om
po
sit
e,
 O
R=
 1
.2
5,
V
SO
M
, O
R=
 1
.8
8),
 an
d S
T 
(co
mp
on
en
ts 
of 
EF
),
O
R=
 1
.5
6.
 S
am
e a
ss
oc
ia
tio
ns
 fo
r p
er
fo
rm
an
ce
le
ve
l o
ut
co
m
es
.
H
ig
he
r l
ev
el
s o
f c
re
at
in
in
e 
w
er
e 
as
so
ci
at
ed
 w
ith
lo
w
er
 le
ve
ls 
of
 p
er
fo
rm
an
ce
 o
n 
th
e 
gl
ob
al
co
m
po
sit
e,
 W
M
, a
nd
 S
T.
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Ta
bl
e 
4
Lo
ng
itu
di
na
l s
tu
di
es
 o
f r
el
at
io
ns
 b
et
w
ee
n 
ki
dn
ey
 fu
nc
tio
n 
an
d 
co
gn
iti
ve
 fu
nc
tio
n 
or
ga
ni
ze
d 
by
 ty
pe
 o
f o
ut
co
m
e 
(se
e i
tal
ics
): 
lev
els
, im
pa
irm
en
t, d
em
en
tia
.
A
ut
ho
rs
, O
ut
co
m
e a
nd
Ti
m
e 
to
 F
ol
lo
w
up
Pr
ed
ic
to
r(s
)
C
on
tr
ol
s:
 a
dju
stm
en
ts 
or
ex
cl
us
io
ns
Sa
m
pl
e
C
og
ni
tiv
e T
es
ts
 o
r
D
ia
gn
os
tic
 C
at
eg
or
y
M
ajo
r s
tat
ist
ica
lly
 si
gn
ific
an
t
fin
di
ng
s1
B
uc
hm
an
 e
t a
l. 
(20
09
)[2
2]
D
ec
lin
e i
n 
pe
rfo
rm
an
ce
o
v
er
 3
.4
 y
ea
rs
.
Co
nt
in
uo
us
 e
G
FR
(M
DR
D)
 at
 ba
sel
ine
 an
d
tr
ic
ho
to
m
iz
ed
 im
pa
ire
d
ki
dn
ey
 fu
nc
tio
n 
at
 b
as
el
in
e
de
fin
ed
 a
s <
45
, >
45
 to
<
60
, >
 6
0.
eG
FR
 a
t b
as
el
in
e,
 a
ge
, s
ex
,
ed
uc
at
io
n,
 B
M
I, 
he
m
og
lo
bi
n,
ph
ys
ic
al
 a
ct
iv
ity
, s
oc
ia
l a
ct
iv
ity
,
v
as
cu
la
r r
isk
 fa
ct
or
s, 
va
sc
ul
ar
di
se
as
es
, d
ep
re
ss
iv
e 
sy
m
pt
om
s.
Ex
cl
us
io
ns
. D
em
en
tia
88
6 
co
m
m
un
ity
- d
w
el
lin
g
pa
rti
ci
pa
nt
s (
me
an
 ag
e=
80
.6
) f
rom
 th
e R
us
h
M
em
or
y 
an
d 
A
gi
ng
 P
ro
jec
t
w
ho
 p
ar
tic
ip
at
ed
 in
 b
ot
h
ba
se
lin
e 
an
d 
fo
llo
w
up
an
al
ys
es
.
5 
su
bs
ca
le
 co
m
po
sit
es
 an
d 
a
gl
ob
al
 c
om
po
sit
e 
de
riv
ed
fro
m
 1
9 
in
di
vi
du
al
m
ea
su
re
s.
 S
ub
sc
al
es
 w
er
e:
ep
iso
di
c 
m
em
or
y,
 se
m
an
tic
m
em
o
ry
, w
or
ki
ng
 m
em
or
y,
pe
rc
ep
tu
al
 sp
ee
d,
v
isu
os
pa
tia
l a
bi
lit
ie
s.
Lo
w
er
 e
G
FR
 a
nd
 im
pa
ire
d 
ki
dn
ey
fu
nc
tio
n 
as
so
ci
at
ed
 w
ith
 ra
te
 o
f
de
cl
in
e 
in
 g
lo
ba
l c
om
po
sit
e,
ep
iso
di
c 
m
em
or
y,
 se
m
an
tic
m
em
o
ry
, a
nd
 w
or
ki
ng
 m
em
or
y.
Ja
ss
al
 
et
 a
l. 
(20
10
)[2
4]
A
nn
ua
l d
ec
lin
e i
n
pe
rfo
rm
an
ce
 le
ve
l o
ve
r
m
ea
n
 fo
llo
w
- u
p 
of
 6
.6
ye
ar
s.
eG
FR
 c
at
eg
or
iz
ed
 a
s ≥
60
o
r 
<
60
 an
d 
al
bu
m
in
ur
ia
(A
CR
 ≥3
0 m
g/g
) v
ers
us
n
o
- 
al
bu
m
in
ur
ia
.
St
ra
tif
ie
d 
by
 se
x.
Co
va
ria
te
s: 
ag
e,
 S
BP
, H
bA
1C
,
ed
uc
at
io
n,
 st
re
nu
ou
s e
xe
rc
ise
,
al
co
ho
l c
on
su
m
pt
io
n,
 c
ur
re
nt
es
tr
og
en
 fo
r w
om
en
, e
G
FR
,
de
pr
es
se
d 
m
oo
d,
 a
nt
ih
yp
er
te
ns
iv
e
m
ed
s, 
lip
id
-lo
w
er
in
g 
m
ed
s,
Ex
cl
us
io
ns
: <
50
 y
ea
rs
 o
f a
ge
,
st
ro
ke
75
9 
co
m
m
un
ity
 d
w
el
lin
g
m
en
 a
n
d 
w
om
en
 (m
ea
n a
ge
-
74
.9
 y
ea
rs
) a
t b
ase
lin
e w
ho
re
tu
rn
ed
 fo
r r
ep
ea
t t
es
tin
g.
M
M
SE
, T
ra
ils
 B
, a
nd
A
ni
m
al
s N
am
in
g 
Ca
te
go
ry
Fl
ue
nc
y 
te
st 
pe
rfo
rm
an
ce
le
ve
ls,
 b
ot
h 
co
nt
in
uo
us
 a
nd
u
sin
g 
cu
t p
oi
nt
s.
Fo
r m
en
 b
ut
 n
ot
 w
om
en
, b
as
el
in
e
al
bu
m
in
ur
ia
, b
ut
 n
ot
 e
G
FR
, w
as
as
so
ci
at
ed
 w
ith
 d
ec
lin
e 
in
 M
M
SE
an
d 
ca
te
go
ry
 fl
ue
nc
y 
sc
or
es
 w
ith
ad
jus
tm
en
t fo
r a
ll c
ov
ari
ate
s.
W
an
g 
et
 a
l. 
(20
10
)[2
8]
D
ec
lin
e i
n 
pe
rfo
rm
an
ce
o
v
er
 4
 y
ea
rs
.
(ye
s/n
o) 
in 
rel
ati
on
 to
ba
se
lin
e 
eG
FR
.
Ca
te
go
rie
s o
f e
G
FR
: ≥
90
(re
fer
en
ce
), 6
0–
89
, 3
0–
59
;
co
n
tin
uo
us
 e
G
FR
 in
se
co
n
da
ry
 a
na
ly
se
s;
al
bu
m
in
ur
ia
 d
ef
in
ed
 a
s ≥
25
 m
g/
g 
fo
r m
al
es
 an
d 
≥
17
 m
g/
g 
fo
r f
em
al
es
.
B
as
ic
: a
ge
, s
ex
, e
du
ca
tio
n,
 B
M
I
A
dd
iti
on
al
: S
BP
, d
ia
be
te
s, 
ur
in
ar
y
A
CR
.
Ex
cl
us
io
ns
: s
tro
ke
1,
24
3 
co
m
m
un
ity
- b
as
ed
Ch
in
es
e 
pa
rti
ci
pa
nt
s (
≥ 4
0
ye
ar
s o
f a
ge
) w
ith
 an
eG
FR
> 
30
; a
nd
 6
6 
ca
se
s o
f
du
rin
g 
a 
4-
ye
ar
 fo
llo
w
up
.
A
 fa
ll 
in
 M
M
SE
 o
f ≥
2
po
in
ts 
fro
m
 b
as
el
in
e 
w
as
de
fin
ed
 a
s c
og
ni
tiv
e
de
cl
in
e.
R
el
at
iv
e 
to
 th
e 
re
fe
re
nc
e 
gr
ou
p,
 ri
sk
o
f d
ec
lin
e 
w
as
 h
ig
he
r f
or
 th
os
e 
w
ith
eG
FR
 o
f 3
0–
59
D
av
ey
 e
t a
l. 
[N
ote
 1]
D
ec
lin
e i
n 
le
ve
l o
f
pe
rfo
rm
an
ce
 (o
ve
r 4
–5
ye
ar
s).
Co
nt
in
uo
us
ly
 d
ist
rib
ut
ed
eG
FR
 a
nd
 1
/sC
R 
an
d
ch
an
ge
 in
 e
G
FR
 b
as
el
in
e
to
 fo
llo
w
up
.
B
as
ic
 c
on
tro
ls:
 a
ge
, e
du
ca
tio
n,
 se
x
ra
ce
/e
th
ni
ci
ty
, e
G
FR
 a
t b
as
el
in
e.
A
dd
iti
on
al
 c
on
tro
ls:
 d
ia
be
te
s,
de
pr
es
se
d 
m
oo
d,
 a
lc
oh
ol
co
n
su
m
pt
io
n,
 d
ia
be
te
s a
nd
hy
pe
rte
ns
io
n,
 A
PO
E 
ge
no
ty
pe
,
sm
o
ki
ng
, a
nd
 c
ar
di
ov
as
cu
la
r
di
se
as
e.
Ex
cl
us
io
ns
, s
tro
ke
 a
t b
as
el
in
e
de
m
en
tia
 a
nd
 re
na
l d
ia
ly
sis
.
59
0 
M
ai
ne
- S
yr
ac
us
e
Lo
ng
itu
di
na
l S
tu
dy
pa
rti
ci
pa
nt
s w
ho
pa
rti
ci
pa
te
d 
at
 b
as
el
in
e 
an
d
fo
llo
w
up
.
D
ec
lin
e 
in
 p
er
fo
rm
an
ce
le
ve
l f
or
 a
bs
tra
ct
 re
as
on
in
g
an
d 
4 
m
ajo
r d
om
ain
s o
f
fu
nc
tio
ni
ng
 b
as
ed
 o
n 
fa
ct
or
an
al
ys
is 
of
 1
9 
se
pa
ra
te
 te
st
sc
o
re
s.
B
as
el
in
e 
le
ve
ls 
of
 e
G
FR
 a
nd
 1
/sC
R
w
er
e 
u
n
re
la
te
d 
to
 lo
ng
itu
di
na
l
ch
an
ge
 b
ut
 c
ha
ng
e 
in
 re
na
l f
un
ct
io
n
(eG
FR
) l
on
git
ud
ina
lly
 w
as
as
so
ci
at
ed
 w
ith
 c
ha
ng
e 
in
 c
og
ni
tiv
e
pe
rfo
rm
an
ce
 fo
r t
he
 g
lo
ba
l
co
m
po
sit
e,
 v
er
ba
l m
em
or
y
co
m
po
sit
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Table 6
Some candidate mechanisms mediating between kidney disease and cognitive functioning on order of
discussion in text.1
CVD Risk Factors Hypertension, chronic hypotension, diabetes mellitus, hyperlipidemia, cardiovascular disease, including myocardial
infarction, arterial fibrillation, cigarette smoking, elevated homocysteine, hemostatic abnormalities,
hypercoagulation, oxidative stress, inflammation, acute stroke,
Biologic Intrinsic Vascular changes in brain; anemia, white matter lesions, anemia, cortical atrophy, hyperparathyroidism,
microalbuminuria, subclinical atherosclerosis
Psychosocial/Treatment Clinical depression and depressed mood and other psychosocial variables, polypharmacy, malnutrition,
Dialysis- related Hypotensive episodes, chronic microembolism, subclinical increases in brain edema, acute stroke, silent and
asymptomatic stroke, hemodynamic changes and fluid shifts, microalbuminuria, recurrent cerebral ischemia, acute
dynamic cardiovascular changes, lacunar infarcts, microbleeds
1See reviews of the literature including references 3–5.
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